Intellectual Property
We have an exclusive license to a patent portfolio created by the original developers of our alphavirus technology -- the University of North Carolina at Chapel Hill and the US Army Medical Research Institute of Infectious Diseases (USAMRIID) . A wide range of patents, and their patent families, have been added to this base. Concomitant with on-going improvements, achieved as the technology has been implemented,, our IP portfolio has been, and continues to be, expanded. Our alphavaccine technology has been the subject of 32 issued US patents, supplemented by a host of foreign counterparts, with many of the patent families pending application or approvals.
US Patents Issued:
5,185,440 cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
5,505,947 Attenuating mutations in Venezuelan Equine Encephalitis virus
5,639,650 cDNA clone for South African Arbovirus No.86
5,643,576 Method of Inducing an immune response with a live VEE virus expressing a heterologous Immunogen
5,792,462 Alphavirus Replicon RNA Systems
5,811,407 System for the In vivo delivery and expression of heterologous genes in the bone marrow
6,008,035 System for the In vivo delivery and expression of heterologous genes in the bone marrow
6,156,558 Alphavirus RNA replicon systems
6,521,235 Alphavirus RNA replicon systems
6,531,135 Alphavirus RNA replicon systems
6,541,010 Alphavirus RNA replicon systems
6,583,121 System for the in vivo delivery and expression of heterologous genes in the bone marrow
6,783,939 Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
6,844,188 Methods and modified cells for the treatment of cancer
6,982,087 Vectors derived from South African Arbovirus No. 86
7,045,335 Alphavirus replicon vector systems
7,078,218 Alphavirus particles and methods for preparation
7,235,235 Alphavirus RNA replicon systems
7,419,674 Alphavirus-based cytomegalovirus vaccines
7,425,337 Alphavirus replicon vector systems
7,442,381 Alphavirus replicons and helper constructs
8,263,092 Alphavirus replicon particles as Immunological adjuvants
8,460,913 Promoterless cassettes for expression of alphavirus structural proteins
8,617,533 Multi-antigenic alphavirus replicon particles and methods
8,680,258 Use of microRNAs to control virus helper nucleic acids
8,709,441 TC-83-derived alphavirus vectors, particles and methods
9,079,943 TC-83-derived alphavirus vectors, particles and methods
9,187,729 Alphavirus and alphavirus replicon particle formulations and methods
9,416,370 Alphavirus replicon particles matched to protein antigens as Immunological adjuvants
9,441,247 TC-83-derived alphavirus vectors ,particles and methods
9,597,414 Use of microRNAs to control virus helper nucleic acids
10,111,943 Alphavirus replicon particles matched to protein antigens as Immunological adjuvants
10,434,187 Use of microRNAs to control virus helper nucleic acids
10,570,416 TC-83-derived alphavirus vectors, particles and methods
Type your paragraph here.
Type your paragraph here.
Vaccines Redefined